NCT03220347CompletedPhase 1
This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 2 Jul 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 127 (actual)
- First submitted
- 30 Jan 2024
- Start date
- 24 Jul 2017
- Lead sponsor
- Celgene Corp.
- NCT number
- NCT03220347
- EU CT number
- 2023-509969-20-00
- EudraCT number
- 2015-004371-79
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 127
- 4 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital Universitario 12 de Octubre Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| IRCCS Istituto Nazionale Tumori Fondazione Pascale Coordinator of this site? Confirm its status | Naples | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.